Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Multiple Myeloma Market Outlook
Thelansis’s “Multiple Myeloma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Multiple Myeloma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Multiple
Myeloma Overview
Multiple
myeloma (MM) is a hematologic malignancy characterized by the uncontrolled
proliferation of clonal plasma cells in the bone marrow, which secrete
significant quantities of non-functional proteins and immunoglobulins. Despite
notable therapeutic advancements over many years, MM remains largely incurable.
These hyperproliferative differentiated B-lymphocytes can produce various types
of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a
lesser extent. Typically, these abnormal plasma cells primarily grow within the
bone marrow, with only a small fraction of patients initially showing
extramedullary disease. Most patients experience relapses during treatment,
progress to a refractory state, and cease to respond to therapy within 60 days
of their last treatment: a grim prognosis and a high likelihood of relapse mark
this. Additionally, with each subsequent relapse, patients endure progressively
shorter periods of progression-free survival (PFS). For instance, PFS for
first-line patients is around 18 months, but by the fourth line of therapy, it
dwindles to a mere 4.7 months.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment